Novartis Global Pipeline

Benefitting from our continued focus on innovation, Novartis has one of the industry’s most competitive pipelines with more than 200 projects in clinical development.

Many of these projects, which include new molecular entities as well as additional indications and different formulations for marketed products, are for medicines that could significantly advance treatment standards for patients worldwide. This table provides an overview of selected projects in development.

For a detailed review of selected projects in confirmatory development, download the complete Novartis Pipeline (PDF 0.1 MB), as of December 31, 2016.

Please note: the Novartis Pipeline data is updated quarterly.

Displaying 41 - 50 of 68 result(s)
New Molecule

LHW090

Resistant hypertension

Cardiovascular and metabolism

Phase II

>=2021

NEP inhibitor

New Molecule

LIK066

Weight loss

Cardiovascular and metabolism

Phase II

>=2021

SGLT1/2 inhibitor

New Molecule

LJN452

Non-alcoholic steatohepatitis

Immunology and dermatology

Phase II

>=2021

FXR agonist

New Molecule

LMI070

branaplam

Spinal muscular atrophy

Neuroscience

Phase III

>=2021

SMN2 RNA splicing modular

New Indication

Lucentis®

ranibizumab

Retinopathy of prematurity

Ophthalmology

Phase III

2018

Anti-VEGF monoclonal antibody fragment

New Molecule

MAA868

Stroke prevention in atrial fibrillation

Cardiovascular and metabolism

Phase II

>=2021

Anti-thrombotic

New Indication

OMB157

ofatumumab

Relapsing multiple sclerosis

Neuroscience

Phase III

2019

Anti-CD20 monoclonal antibody

New Indication

PDR001

Neuroendocrine tumors

Oncology

Phase III

2019

PD-1 Inhibitor

New Molecule

PDR001 + Taf/Mek

Metastatic BRAF V600+ melanoma

Oncology

Phase III

2019

PD-1 Inhibitor

New Molecule

PIM447

Hematologic cancers

Oncology

Phase I

>=2021

Pan-PIM inhibitor

Pages

Legend

Combination abbreviations:
fulv fulvestrant
tmx tamoxifen
gsn goserelin
NSAI Non-steroidal aromatase inhibitor
Taf Tafinlar® (dabrafenib)
Mek Mekinist® (trametinib)
a EU filing, approved in US.
b US filing, approved in EU.
c US filing, submitted in EU.
d Lubris LLC transaction announced in April 2017.
e Conatus transaction for exclusive global license for emricasan announced in May 2017.

Disclaimer

This information was factually accurate on the date it was published. Novartis assumes no duty to update the information to reflect subsequent developments. Readers should not rely upon the information on this page as current or accurate after its publication date. For the latest information on the Novartis' pipeline, readers should visit the News and Investors sections of our website. This information constitutes forward-looking statements relating to Novartis AG's business, including express or implied discussions regarding potential new products, potential new indications for existing products, or regarding potential future revenues from any such products. Such forward-looking statements reflect the current views of Novartis AG regarding future events, and involve known and unknown risks, uncertainties and other factors that may cause actual results to be materially different from any future results, performance or achievements expressed or implied by such statements. There can be no guarantee that any new products will be approved for sale in any market, or that any new indications will be approved for existing products in any market, or that such products will achieve any particular revenue levels.

In particular, management's expectations could be affected by, among other things, uncertainties involved in the development of new pharmaceutical products; unexpected clinical trial results, including additional analysis of existing clinical data or unexpected new clinical data; unexpected regulatory actions or delays or government regulation generally; the Novartis Group's ability to obtain or maintain patent or other proprietary intellectual property protection, including the uncertainties involved in the US litigation process; competition in general; government, industry, and general public pricing and other political pressures; and other risks and factors referred to in Novartis AG's current Form 20-F on file with the US Securities and Exchange Commission. Should one or more of these risks or uncertainties materialize, or should underlying assumptions prove incorrect, actual results may vary materially from those described herein as anticipated, believed, estimated or expected.